Metabolic diseases

The category metabolic diseases as defined by the G-BA lists medicinal products for diseases such as diabetes mellitus, certain metabolic enzyme defects such as cystic fibrosis (CF) and hypercholesterolaemia. To date, the G-BA has assessed 82 medicinal products in 186 resolutions. In total, 352 patient populations have been formed. Weighted by patient share in the respective resolution, a major additional benefit has been proved for 3.4% of the subpopulations, with a considerable additional benefit for 5.5%%. A minor additional benefit has been identified for 10.1% of the subpopulations, whereas 27.5% have seen a non-quantifiable additional benefit.
The G-BA has seen no additional benefit proven for 53.1% of the subpopulations. This corresponds to 81% of the total 50.68 million patients suitable for the assessed medicinal product but for whom no additional benefit was proven in relation to the comparative therapy.